TICKERNERD
Menu
MYOMYOHealthcare · Medical Devices

MYO Stock Forecast: Myomo, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.73
−0.57% on the day

The 5 Wall Street analysts covering Myomo, Inc. hold a median 12-month price target of $3 — +73.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$68.5M
Ticker Nerd rank
45 / 100
Median analyst target
$3.00
Analysts covering
5
Total return, dividends reinvested
1W
+0.6%
1M
+85.0%
YTD
+90.1%
1Y
+54.5%
From 52W high
−7.0%
From 52W low
+170.3%
$0.64
$1.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MYO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Myomo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Size
80
Quality
75
Revisions
60
Value
46
Growth
30
Momentum
28
Issuance
10
Volatility
10

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MYO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MYO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26MYOHigh $10.00Median $3.00Low $1.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $1.70Median $3.00High $10.00

The green dot is the last close — the median target sits +73.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026Ascendiant CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Craig-HallumMaintainsBuy—
5 June 2025Ascendiant CapitalMaintainsBuy—
8 May 2025Craig-HallumMaintainsBuy—
17 Mar 2025Ascendiant CapitalMaintainsBuy—
12 Mar 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Craig-HallumMaintainsBuy—
13 Dec 2024Craig-HallumMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$7.50
12 Nov 2024Ascendiant CapitalMaintainsBuy—
19 Aug 2024Ascendiant CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
31 July 2024Craig-HallumInitiatesBuy—
9 July 2024Lake StreetMaintainsBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
15 Dec 2023HC Wainwright & Co.InitiatesBuy—
25 May 2023Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MYO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MYO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Myomo, Inc. (MYO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.7×

Cheaper than 89% of US stocks

Price / sales
1.6×

Cheaper than 59% of US stocks

Price / book
11.8×

Cheaper than 9% of US stocks

EV / EBITDA
−7.1×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
21.3%

Higher than 71% of US stocks

Earnings growth (YoY)
21.3%

Higher than 60% of US stocks

Gross margin
72.1%

Higher than 84% of US stocks

Operating margin
−19.3%

Higher than 22% of US stocks

Net margin
−33.5%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−123.8%

Higher than 11% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MYO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MYOMyomo, Inc.$68.5M
45
NNOXNano-X Imaging Ltd.$67.6M
27
CVRXCVRx, Inc.$74.7M
34
OMOutset Medical, Inc.$77.0M
29
COCHEnvoy Medical, Inc.$57.7M
34
RPIDRapid Micro Biosystems, Inc.$83.7M
32
SERASera Prognostics, Inc.$83.8M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Myomo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MYO news & analysis

Myomo Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Myomo reported 21% revenue growth for the second quarter of 2026. The wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships, as highlighted in its earnings call.

Why it matters — A Myomo watcher would care because continued revenue growth and a stronger recurring referral and reimbursement model signal improving commercial traction for its wearable robotics business.

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Myomo, Inc.'s Q2 2026 earnings call, providing the company's discussion of its quarterly results. The item signals that the earnings call transcript is now available to investors.

Why it matters — A MYO watcher would look to this transcript for management's firsthand commentary on the company's second-quarter performance and outlook.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Myomo, Inc. reported a second-quarter loss of $0.07 per share, which was narrower than the Zacks Consensus Estimate of a $0.10 loss and better than the $0.11 loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — MYO watchers would care because the results came in better than consensus expectations on both the loss and revenue side, signaling improved performance relative to forecasts.

Myomo Reports Second Quarter 2026 Financial and Operating Results

Business Wire · 5 Aug 2026positive

Myomo reported its financial results for the three and six months ended June 30, 2026. The company said its evolving go-to-market approach is driving positive results, with revenue of $11.7 million exceeding expectations, with 53% of that figure not fully described in the excerpt.

Why it matters — A MYO watcher would note that the company's reported revenue exceeded its expectations, signaling that changes to its go-to-market strategy are producing positive outcomes in the quarter.

Myomo to Report Second Quarter 2026 Financial Results on August 5

Business Wire · 29 July 2026neutral

Myomo announced it will report financial results for the second quarter ended June 30, 2026 on August 5, 2026, and management will hold a conference call at 4:30 p.m. Eastern time to review the results and provide a business update.

Why it matters — The announcement signals the upcoming release of Myomo's latest quarterly financial performance and management's assessment of the business, which investors use to evaluate the company's trajectory.

FAQ

Frequently asked questions about MYO stock

What is the MYO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Myomo, Inc. have a median 12-month price target of $3, with estimates ranging from $1.7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MYO stock a buy right now?

Of the 5 analysts covering Myomo, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Myomo, Inc. 45 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MYO?

As at 22 Aug 2026, Myomo, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will MYO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +73.4% from the last close, and Ticker Nerd's factor model ranks Myomo, Inc. 45 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MYO stock forecast for 2030?

No analyst covering Myomo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.7 to $10 over the next 12 months.

How has MYO stock performed over the past year?

Myomo, Inc. returned +54.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Myomo, Inc. do?

Myomo Inc. is a pioneering company in the field of medical robotics, specializing in the development and production of powered brace systems, specifically for upper-extremity mobility enhancement.

What is the latest news on MYO?

The most recent item we track (MarketBeat, 9 Aug 2026): "Myomo Q2 Earnings Call Highlights". Myomo reported 21% revenue growth for the second quarter of 2026. The wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships, as highlighted in its earnings call.

Company

About Myomo, Inc.

Myomo Inc. is a pioneering company in the field of medical robotics, specializing in the development and production of powered brace systems, specifically for upper-extremity mobility enhancement. These orthotic devices, branded under the name MyoPro, are designed to assist individuals dealing with neuromuscular malfunctions such as those caused by stroke, brachial plexus injury, or other neurological conditions. The primary function of MyoPro is to help users restore functionality and independence in their arms through advanced sensor technology that detects and amplifies the user's own muscle signals. Operating at the intersection of healthcare and technology, Myomo Inc. serves a vital role in the rehabilitation industry, transforming the lives of patients who previously had limited options for recovery. By providing a non-invasive solution to regain strength and mobility, the company's products are significant in addressing a growing need within the healthcare market. Myomo's innovative approach to patient care positions it as an influential player in the medical device sector, contributing to advancements in prosthetics and orthotics.

CEO Mr. Paul R. Gudonis · 194 employees · United States · https://myomo.com